Journal: Experimental and Therapeutic Medicine

Article Title: Metformin reduces chondrocyte pyroptosis in an osteoarthritis mouse model by inhibiting NLRP3 inflammasome activation

doi: 10.3892/etm.2022.11146

Figure Lengend Snippet: Metformin can decrease chondrocyte pyroptosis in a destabilization of the medial meniscus model at the protein level. (A) NLRP3, (B) caspase-1, (C) GSDMD and (D) IL-1β immunohistochemistry test results (magnification, x400). Scale bar=100 µm. Black arrows indicate the positive cells. The ratio of positive cells immunoreactive for (E) NLRP3, (F) caspase-1, (G) GSDMD and (H) IL-1β. One-way ANOVA followed by Tukey's multiple comparison test was used to compare data among groups after testing the data for homogeneity of variance. *** P<0.001; ### P<0.001. NLRP3, NOD-like receptor protein 3; GSDMD, gasdermin D.

Article Snippet: Next, the sections were blocked with 5% normal goat serum (OriGene Technologies, Inc.) at 37˚C for 30 min and incubated overnight at 4˚C with the following primary antibodies: Anti-MMP-13 (cat. no. ab39012; 1:300 dilution; Abcam), anti-Col II (cat. no. ab34712; 1:300 dilution; Abcam), anti-NLRP3 (cat. no. ab214185; 1:200 dilution; Abcam), anti-caspase-1 (cat. no. 22915-1-AP; 1:200 dilution; ProteinTech Group, Inc.), anti-GSDMD (cat. no. ab219800; 1:200 dilution; Abcam) and anti-IL-1β (cat. no. ab205924; 1:300 dilution; Abcam).

Techniques: Immunohistochemistry

Journal: Experimental and Therapeutic Medicine

Article Title: Metformin reduces chondrocyte pyroptosis in an osteoarthritis mouse model by inhibiting NLRP3 inflammasome activation

doi: 10.3892/etm.2022.11146

Figure Lengend Snippet: Metformin can decrease chondrocyte pyroptosis in a destabilization of the medial meniscus model at gene level. Relative expression levels of (A) NLRP3, (B) caspase-1, (C) GSDMD and (D) IL-1β mRNA. One-way ANOVA followed by Tukey's multiple comparison test was used to compare data among groups after testing the data for homogeneity of variance. * P<0.05 and *** P<0.001; # P<0.05; ## P<0.01; ### P<0.001. NLRP3, NOD-like receptor protein 3; GSDMD, gasdermin D.

Article Snippet: Next, the sections were blocked with 5% normal goat serum (OriGene Technologies, Inc.) at 37˚C for 30 min and incubated overnight at 4˚C with the following primary antibodies: Anti-MMP-13 (cat. no. ab39012; 1:300 dilution; Abcam), anti-Col II (cat. no. ab34712; 1:300 dilution; Abcam), anti-NLRP3 (cat. no. ab214185; 1:200 dilution; Abcam), anti-caspase-1 (cat. no. 22915-1-AP; 1:200 dilution; ProteinTech Group, Inc.), anti-GSDMD (cat. no. ab219800; 1:200 dilution; Abcam) and anti-IL-1β (cat. no. ab205924; 1:300 dilution; Abcam).

Techniques: Expressing

Journal: BMC Veterinary Research

Article Title: Stability of canine and feline cerebrospinal fluid samples regarding total cell count and cell populations stored in “TransFix®/EDTA CSF sample storage tubes”

doi: 10.1186/s12917-020-02698-5

Figure Lengend Snippet: Used antibodies for the flow cytometry

Article Snippet: 3 , Isotype CD45 AF 647 , RAT IgG2b negative Contral AlexaFluor 647; SeroTec, Hercules, USA , MCA1125A647 , 5 μl 11:1 , , R1/Red 635 nm.

Techniques: Concentration Assay, Negative Control, Control

Journal: Allergy

Article Title: Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern

doi: 10.1111/all.15311

Figure Lengend Snippet: Intranasal administration of CuMV TT ‐RBD induces a systemic RBD‐ and spike‐specific IgG response of high avidity. (A) Vaccination regimen and bleeding schedule. (B, C) RBD‐specific IgG titer on Days 0, 7, 14, 21, 35, 42, and 49 from mice immunized with CuMV TT ‐RBD vaccine or CuMV TT control measured by ELISA, OD 450 shown in B, LOG 10 OD 50 shown in C. (D, E) Spike‐specific IgG titer on Days 0, 7, 14, 21, 35, 42, and 49 from mice immunized with CuMV TT ‐RBD vaccine or CuMV TT control measured by ELISA, OD 450 shown in D, LOG 10 OD 50 shown in E. (F) RBD‐specific IgG titer at Day 49 from mice immunized with CuMV TT ‐RBD vaccine, LOG 10 OD 50 shown. (G) Avidity index. Statistical analysis (mean ± SEM) using one‐way ANOVA (C and E) and Student's t ‐ test (F). Control group n = 6 , vaccine group n = 6 . One representative of 2 similar experiments is shown

Article Snippet: The following secondary Abs have been used: Rat anti‐mouse IgG1 (BD Pharmingen, Cat. 559626, 1:2000 dilution), biotinylated mouse anti‐mouse IgG2a (Clone R19‐15, BD Biosciences, Cat No 553391, USA, 1:2000 dilution), goat anti‐mouse IgG2b (Invitrogen, Ref. M32407, 1:2000 dilution), and goat anti‐mouse IgG3 (Southern BioTech, Cat No 1101‐05, 1:2000 dilution).

Techniques: Control, Enzyme-linked Immunosorbent Assay

Journal: Allergy

Article Title: Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern

doi: 10.1111/all.15311

Figure Lengend Snippet: Intranasal immunization with CuMV TT ‐RBD promotes isotype switching to IgA and leads to balanced IgG subclass responses. (A) RBD‐specific IgG1, IgG2a, IgG2b, and IgG3 titer for the groups vaccinated with CuMV TT ‐RBD vaccine or CuMV TT control on Day 42 measured by ELISA, LOG 10 OD 50 shown. (B) RBD‐specific IgA titer for the groups vaccinated with CuMV TT ‐RBD vaccine or CuMV TT control on Day 42 measured by ELISA, OD 450 shown. (C) RBD‐specific IgA titer at Day 42 from mice immunized with CuMV TT ‐RBD vaccine, LOG 10 OD 50 shown. Plates in duplicates: treated with PBSTween or 7 M urea. (D) Avidity index of RBD‐specific IgA titer. Statistical analysis (mean ± SEM) using Student's t ‐ test . Control group n = 6 , vaccine group n = 6 . One representative of 2 similar experiments is shown

Article Snippet: The following secondary Abs have been used: Rat anti‐mouse IgG1 (BD Pharmingen, Cat. 559626, 1:2000 dilution), biotinylated mouse anti‐mouse IgG2a (Clone R19‐15, BD Biosciences, Cat No 553391, USA, 1:2000 dilution), goat anti‐mouse IgG2b (Invitrogen, Ref. M32407, 1:2000 dilution), and goat anti‐mouse IgG3 (Southern BioTech, Cat No 1101‐05, 1:2000 dilution).

Techniques: Control, Enzyme-linked Immunosorbent Assay

Journal: Allergy

Article Title: Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern

doi: 10.1111/all.15311

Figure Lengend Snippet: CuMV TT ‐RBD induced immune sera is able to recognize VOCs. RBD wt and VOCs‐specific IgG titers on Day 0 and Day 49 for the group vaccinated with CuMV TT ‐RBD measured by ELISA, OD 450 in A, LOG 10 OD 50 in B. Statistical analysis (mean ± SEM) using one‐way ANOVA. Control group n = 6 , vaccine group n = 6 . One representative of 2 similar experiments is shown

Article Snippet: The following secondary Abs have been used: Rat anti‐mouse IgG1 (BD Pharmingen, Cat. 559626, 1:2000 dilution), biotinylated mouse anti‐mouse IgG2a (Clone R19‐15, BD Biosciences, Cat No 553391, USA, 1:2000 dilution), goat anti‐mouse IgG2b (Invitrogen, Ref. M32407, 1:2000 dilution), and goat anti‐mouse IgG3 (Southern BioTech, Cat No 1101‐05, 1:2000 dilution).

Techniques: Enzyme-linked Immunosorbent Assay, Control

Journal: Allergy

Article Title: Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern

doi: 10.1111/all.15311

Figure Lengend Snippet: RBD‐ and spike‐specific IgG and IgA were detected locally in BAL, with RBD‐specific IgG2b dominating the local subclass response (A–C) RBD‐ (A, C) and spike‐ (B, C) specific IgG titer in BAL for the groups vaccinated with CuMV TT ‐RBD vaccine or CuMV TT control, measured by ELISA, OD 450 shown in A, B, LOG 10 OD 50 shown in C. (D–F) RBD‐ (D, F) and spike‐ (E, F) specific IgA titer in BAL for the groups vaccinated with CuMV TT ‐RBD vaccine or CuMV TT control, measured by ELISA, OD 450 shown in D, E, LOG 10 OD 50 shown in F. (G) RBD‐specific IgG1, IgG2a, IgG2b, and IgG3 titer in BAL for the groups vaccinated with CuMV TT ‐RBD vaccine or CuMV TT control, measured by ELISA, LOG 10 OD 50 shown. (H) RBD‐specific IgA titer in BAL from mice immunized with CuMV TT ‐RBD vaccine, LOG 10 OD 50 shown. Plates in duplicates: treated with PBSTween or 7 M urea. (I) Avidity index of RBD‐specific IgA titer. (J) Avidity indexes of RBD‐specific IgA Abs found in BAL and serum after CuMV TT ‐RBD immunization. Statistical analysis (mean ± SEM) using Student's t ‐ test . Control group n = 6 , vaccine group n = 6 . One representative of 2 similar experiments is shown

Article Snippet: The following secondary Abs have been used: Rat anti‐mouse IgG1 (BD Pharmingen, Cat. 559626, 1:2000 dilution), biotinylated mouse anti‐mouse IgG2a (Clone R19‐15, BD Biosciences, Cat No 553391, USA, 1:2000 dilution), goat anti‐mouse IgG2b (Invitrogen, Ref. M32407, 1:2000 dilution), and goat anti‐mouse IgG3 (Southern BioTech, Cat No 1101‐05, 1:2000 dilution).

Techniques: Control, Enzyme-linked Immunosorbent Assay

Journal: Allergy

Article Title: Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern

doi: 10.1111/all.15311

Figure Lengend Snippet: Intranasal administration of CuMV TT ‐RBD induced RBD‐specific IgG and IgA plasma cells locally and systemically. (A–C) Number of RBD specific IgG and IgA secreting cells per 2 × 10 6 seeded cells in spleen (A), BM (B) or per 2 × 10 5 seeded cells in lung (C) after immunization with CuMV TT ‐RBD vaccine or CuMV TT control, detected by Fluorospot. (D–F) Representative pictures of wells seeded with cells out of spleen (D), BM (E), lung (F). Statistical analysis (mean ± SEM) using Student's t ‐ test . Control group n = 6 , vaccine group n = 6 . One representative of 2 similar experiments is shown

Article Snippet: The following secondary Abs have been used: Rat anti‐mouse IgG1 (BD Pharmingen, Cat. 559626, 1:2000 dilution), biotinylated mouse anti‐mouse IgG2a (Clone R19‐15, BD Biosciences, Cat No 553391, USA, 1:2000 dilution), goat anti‐mouse IgG2b (Invitrogen, Ref. M32407, 1:2000 dilution), and goat anti‐mouse IgG3 (Southern BioTech, Cat No 1101‐05, 1:2000 dilution).

Techniques: Clinical Proteomics, Control

Journal: Allergy

Article Title: Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern

doi: 10.1111/all.15311

Figure Lengend Snippet: Antibodies induced by intranasal vaccination are capable of neutralizing SARS‐CoV‐2 and its variants. (A) BLI‐evaluation of ACE2 binding to RBD in the presence of vaccinated mice sera or controls. (B) Percentage of ACE2 to RBD binding inhibition of the individual mice vaccinated with CuMV TT ‐RBD, control mouse vaccinated with CuMV TT (C1), with no serum and naïve mouse. (C) Correlation of RBD‐specific LOG 10 OD 50 IgG titer with the percentage of ACE2 to RBD binding inhibition from individual mice sera. Statistical analysis (mean ± SEM) using Pearson Correlation test. (D) Neutralization titer against SARS‐CoV‐2 wt, SA and UK isolates. Statistical analysis (mean ± SEM) using Student's t ‐ test . Control group n = 1 in a, b, c, n = 5 for D, vaccine group n = 6 for A , B , C , n = 5 for D . One representative of 2 similar experiments is shown

Article Snippet: The following secondary Abs have been used: Rat anti‐mouse IgG1 (BD Pharmingen, Cat. 559626, 1:2000 dilution), biotinylated mouse anti‐mouse IgG2a (Clone R19‐15, BD Biosciences, Cat No 553391, USA, 1:2000 dilution), goat anti‐mouse IgG2b (Invitrogen, Ref. M32407, 1:2000 dilution), and goat anti‐mouse IgG3 (Southern BioTech, Cat No 1101‐05, 1:2000 dilution).

Techniques: Binding Assay, Inhibition, Control, Neutralization